hrp0086p2-p759 | Pituitary and Neuroendocrinology P2 | ESPE2016

A Case of Central Precocious Puberty in a Patient with Prader-Willi Syndrome

Pellegrin Maria Chiara , Tornese Gianluca , Faleschini Elena , Ventura Alessandro

Background: Hypogonadism is one of the major diagnostic criteria of Prader-Willi syndrome (PWS). A hypogonadotropic hypogonadism is often present as a result of hypothalamic dysfunction (together with other hormonal disorders, such as growth hormone deficiency and hypothyroidism).Presentation: A 8.5-year-old boy with genetically-confirmed PWS (maternal uniparental disomy) presented in our Endocrinology Unit for routinely follow-up. Therapy with rhGH was ...

hrp0084p3-1020 | Growth | ESPE2015

GH Deficiency and Glucose 1 Transporter Deficiency Syndrome

Patti Giuseppa , Tornese Gianluca , Costa Paola , Faleschini Elena , Ventura Alessandro

Background: GLUT1 deficiency syndrome (GLUT1DS) is a treatable epileptic encephalopathy resulting from impaired glucose transport into the brain. Clinical features comprise motor and mental developmental delay, seizures with infantile onset, deceleration of head growth often resulting in acquired microcephaly, and a movement disorder with ataxia, dystonia, and spasticity. While it is known that ketogenic diet may cause growth retardation, GH deficiency (GHD) may represent anot...

hrp0098p2-149 | GH and IGFs | ESPE2024

Real-world experience of using Long-Acting Growth Hormone Somatrogon in children and adolescents with growth hormone deficiency

Tamaro Gianluca , Rodaro Chiara , Faleschini Elena , Tornese Gianluca

Background: The first Long-Acting Growth Hormone (LAGH) therapy, Somatrogon, has been available in Italy since March 2023 for children with growth hormone deficiency (GHD) older than 3 years, offering a convenient way of administering the treatment once weekly instead of once daily. Clinical trials have demonstrated the efficacy and safety of LAGH treatment in children with GHD. We aim ed to evaluate the real-world experience of using Somatrogon at a tertiary ...

hrp0089p2-p266 | Growth & Syndromes P2 | ESPE2018

A Novel FGFR1 Mutation in Kallmann Syndrome with Growth Hormone Deficiency

Tornese Gianluca , Pellegrin Maria Chiara , Pavan Matteo , Faleschini Elena , Barbi Egidio

Background: Kallmann syndrome (KS) is a genetic disorder, mainly characterized by the association of anosmia (due to hypo/aplasia of the olfactory bulbs) and hypogonadotropic hypogonadism (due to GnRH deficiency). Both partial or complete forms are described. Other features (skeletal and renal malformations, deafness, bimanual synkinesis) can be variably associated. Behind this phenotypic heterogeneity, there is a considerable complexity of genetic mutations. KAL1, <e...

hrp0086p1-p824 | Syndromes: Mechanisms and Management P1 | ESPE2016

Growth Hormone Deficiency in Noonan Syndrome: Does it Influence Clinical Response to GH Therapy?

Pellegrin Maria Chiara , Tornese Gianluca , Faleschini Elena , Masera Nicoletta , Pozzobon Gabriella , Selicorni Angelo , Ventura Alessandro

Background: Short stature is a main feature of Noonan syndrome (NS). Although rhGH is commonly used in NS patients, it is not known whether a defect in the secretion of GH influences the response to rhGH therapy.Objective and hypotheses: The aim of this study was to evaluate the efficacy and safety of rhGH treatment in NS patients, according to the presence of GH deficiency at the baseline.Method: We retrospectively collected data ...

hrp0082p2-d3-392 | Fat Metabolism &amp; Obesity (2) | ESPE2014

HbA1c and Metabolic Parameters in a Pediatric Overweight/Obese Population

Pellegrin Maria Chiara , Grillo Andrea , Faleschini Elena , Tornese Gianluca , Ventura Alessandro

Background: HbA1c was recommended as diagnostic tool in adults at risk for diabetes. In obese patients, HbA1c shows an association even with other features of metabolic syndrome. However, its value in pediatric population for this purpose has yet to be established.Material and methods: We determined HbA1c (IFCC method) in 307 overweight/obese children and adolescents (age 11.4±3.2; range 3.0–17.9 and BMI 27.9±4.7; range 20.4–47.6) val...

hrp0084p2-357 | Fat | ESPE2015

TG:HDL Ratio as Best Predictor for IGT Screening in Overweight Children

Pellegrin Maria Chiara , Radillo Lucia , Grillo Andrea , Tornese Gianluca , Faleschini Elena , Ventura Alessandro

Background: The prevalence of dysglycaemia is high among overweight children and adolescents. Current screening criteria with fasting laboratory values have low sensitivity to detect IGT. Fasting triglycerides (TG) >1.17 mmol/l has been proposed as a criterion for screening obese children and adolescents at risk for IGT.Aims and objectives: We aimed to compare the performance of different screening criteria for detecting IGT in obese and overweight c...

hrp0097p1-95 | GH and IGFs | ESPE2023

Clinical and laboratory characteristics in children with growth hormone deficiency (GHD) and short stature unresponsive to stimulation tests (SUS)

Dalla Bona Eva , Andrea Lanzetta Maria , Tamaro Gianluca , Faleschini Elena , Tornese Gianuca

Background: It has been previously proposed that not all children with short stature displaying an inadequate response to tests for growth hormone (GH) secretion truly suffer from GH deficiency (GHD). Instead, amongst these, solely children with an identifiable monogenic cause of GHD or an identifiable functional or anatomical anomaly in the hypothalamic-pituitary axis should be considered GHD. The remaining patients should be defined as affected by “sho...

hrp0097p1-180 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2023

Clinical, radiological and laboratory characteristics of thelarche variant: a retrospective analysis

Tamaro Gianluca , Lorenzon Beatrice , Burlo Francesca , Peinkhofer Martina , Faleschini Elena , Tornese Gianluca

Background: ‘Thelarche variant’ (TV), also known as ‘unsustained/slowly progressive puberty’ or ‘exaggerated thelarche’, is a term used to describe girls with premature thelarche and intermediate features between isolated premature thelarche (PT) and central precocious puberty (CPP). Despite being characterized by a FSH predominant response and by a peak LH response <5 IU/L to GnRH test, a univocal definition is lacking.<...

hrp0092lb-18 | Late Breaking Posters | ESPE2019

Exploratory Case-Control Study on ACE2 Expression in Children with Short Stature

Tornese Gianluca , Tonon Federica , Nicolardi Francesca , Chiara Pellegrin Maria , Toffoli Barbara , Faleschini Elena , Barbi Egidio , Fabris Bruno , Bernardi Stella

Background: Short stature is one of the most common presentations to paediatric endocrinologists. It is estimated that despite all the exams, in 50–90% of cases, children are labeled as having idiopathic short stature. It has been recently reported that genetic ACE2 deficiency is associated with reduced body weight as well as with impaired gestational weight gain and fetal growth restriction in pregnancy. It has been argued that ACE2 deficiency, which...